Spectinomycin Hydrochloride for Injection is a medication for urinary tract infections caused by Neisseria gonorrhoeae. It is mainly used for infections caused by drug-resistant strains such as penicillin and tetracycline.

The global Spectinomycin Hydrochloride for Injection market was valued at US$ XX million in 2020 and is expected to reach US$ XX million by the end of 2027, growing at a CAGR of XX% during 2021-2027.
This report focuses on Spectinomycin Hydrochloride for Injection volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Spectinomycin Hydrochloride for Injection market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.

Global Spectinomycin Hydrochloride for Injection Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type
Human Use
Dog Use

Segment by Application
Urinary Tract Infection Caused by Neisseria Gonorrhoeae
Rectal Infection Caused by Neisseria Gonorrhoeae
Others

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE

By Company
Zhejiang Hisun Pharmaceutical Co., Ltd.
Sinopharm Group Guorui Pharmaceutical Co., Ltd.
Zhejiang Jinhua Kangenbei Biopharmaceutical Co., Ltd.
Shandong Lukang Pharmaceutical Co., Ltd.
Anhui Wellman Pharmaceutical Co., Ltd.
Jiangsu Muwang Technology Industrial Co., Ltd.